INTRODUCTION
============

The Duffy (FY) blood group system (The International Society of Blood Transfusion \[ISBT\] 008) was first reported in 1950, when anti-Fy^a^ was observed in a hemophiliac patient with a serious hemolytic transfusion reaction following multiple blood transfusions \[[@B1]\]. One year later, anti-Fy^b^ was discovered in a case of hemolytic disease of the fetus and newborn (HDFN) \[[@B2]\]. Generally, four Duffy phenotypes, Fy(a+b-), Fy(a-b+), Fy(a+b+), and Fy(a-b-), are defined according to the antibodies anti-Fy^a^ and anti-Fy^b^. A high frequency of the Fy^a^ phenotype has been described among Asian populations, ranging from 87.4% to 99.9% \[[@B3][@B4][@B5][@B6]\]. Although the Fy(a-b-) phenotype is commonly found in African populations, it is extremely rare in Asian populations \[[@B3][@B4][@B5][@B6][@B7]\]. After alloimmunization by transfusion or during a pregnancy, anti-Fy3 can be detected, making it difficult to find compatible blood donors when a patient requires blood transfusions \[[@B7]\].

On the basis of a previous study in Thailand, the most common alloantibodies found in multitransfused patients are those in the Rh system (42.2%), followed by the MNS system (31.9%), and the Kidd system (10.5%) \[[@B8]\]. In the Duffy system, anti-Fy^b^ is frequently found in combination with Rh and other antibodies (2.6%), whereas anti-Fy^a^ is found as a single antibody (0.1%) \[[@B8]\]. Moreover, a positive direct antiglobulin test (DAT) is often found in patients with repeated transfusions; thus, Duffy DNA-based genotyping can be used as an alternative to conventional phenotyping in clinical situations, e.g., for finding matched blood for alloimmunized patients, assessing the risk of HDFN, and studying anthropology and disease associations \[[@B9][@B10]\].

The *FY* gene has three major alleles, *FY^\*^A*, *FY^\*^B*, and FY^\**ES*^ (ES, erythrocyte silent), and is located on chromosome 1 at position q22-q23. The *FY^\*^A* and *FY^\*^B* polymorphism is caused by a missense point mutation at c.125G\>A, resulting in a p.Gly42Asp substitution, which encodes the Fy^a^ and Fy^b^ antigens \[[@B6][@B11][@B12]\]. In addition, a single mutation in a GATA motif in the *FY*^\**ES*^ promoter at c.-33T\>C causes a non-expression antigen in FY-negative individuals \[[@B11][@B12][@B13]\]. Current DNA technology for FY blood group genotyping enables the detection of *FY* alleles. Various PCR-based methods including allele-specific PCR (AS-PCR), PCR-restriction fragment length polymorphism (PCR-RFLP), PCR with sequence-specific primer (PCR-SSP) as single or multiplex assays, real-time quantitative PCR, high-resolution melting analysis, and DNA microarray hybridization have been used for blood group genotyping \[[@B11][@B12][@B14][@B15][@B16][@B17][@B18]\]. Although the Duffy blood group phenotypes in Thai blood donors have been studied \[[@B5][@B19]\], the *FY* allele frequencies in this group have not been investigated to date. In this study, the *FY* allele frequencies in Thai blood donors were determined by in-house PCR-SSP, and the probability of obtaining compatible blood for alloimmunized patients was assessed.

METHODS
=======

1. Subjects
-----------

Peripheral venous blood was collected in EDTA tubes from 500 unrelated, healthy Thai blood donors at the National Blood Centre, Thai Red Cross Society, Bangkok, Thailand from May to July 2014, and the study was performed until December 2014. The donors were from central Thailand and their ages ranged from 19 to 58 yr. Informed consent was obtained from each subject. This study was approved by the Committee on Human Rights Related to Research Involving Human Subjects, Thammasat University, Pathumtani, Thailand. Genomic DNA was extracted from all samples by using the Genomic DNA Extraction Kit (REAL Genomics, RBC Bioscience, Taipei, Taiwan) and was stored at -20℃ until use.

In addition, four DNA samples from a family of Guinea origin with Fy(a-b-) phenotypes consisting of a mother, father, and twins were included to confirm the serological testing results. All samples obtained from this family were subjected to FY phenotyping at the National Blood Centre, Thai Red Cross Society, Bangkok, Thailand.

2. DNA standards
----------------

Nine DNA samples with known phenotypes confirmed by DNA sequencing, including three Fy(a+b-), three Fy(a-b+), and three Fy(a+b+) phenotypes, were used as controls. Moreover, two DNA samples from individuals with Fy(a-b-) phenotypes of *FY^\*^B^ES^* (c.-33C) were also included.

3. Duffy blood group phenotyping using the gel technique
--------------------------------------------------------

A 1% RBC suspension in Diluent-II (Bio-Rad, Morat, Switzerland) was prepared. Fifty microliters of RBC suspension and 50 µL of anti-Fy^a^ and/or anti-Fy^b^ were added to the appropriate microtube with the ID-Card \"Diaclon anti-Fy^a^\" and/or \"Diaclon anti-Fy^b^\" (Bio-Rad). The ID-card was incubated for 15 min at 37℃ and was centrifuged for 10 min in the ID-centrifuge (Dia-Med AG, Morat, Switzerland). The results were read and recorded according to the manufacturer\'s instructions. A total of 200 blood samples from Thai blood donors were tested by FY phenotyping.

4. Duffy blood group genotyping by PCR-SSP
------------------------------------------

Duffy blood group was genotyped was performed by using the PCR-SSP technique, following previously described methods \[[@B11]\] with some modifications. Individual FY genotyping tests included four sets of PCR reaction mixtures. For each PCR reaction, 1 µL of genomic DNA (50 ng/µL) was amplified in a total volume of 20 µL by using 1 µL of forward primers for the *FY* promoter region polymorphism (GATA-AB-F/FY-AB-F) and 1 µL of reverse primer for the *FY^\*^A* and *FY^\*^B* polymorphism (FY-A-R/FY-B-R). Sequences of the primer combinations used in the four primer mixtures and the allele detected by each mixture are shown in [Table 1](#T1){ref-type="table"}. In addition, co-amplification of the human growth hormone gene (*HGH*) using 1 µL of the HGH-F primer and 1 µL of the HGH-R primer was run as an internal control. The PCR was performed with 10 µL of the PCR reaction mixture (OnePCR Plus, GeneDirex, New Taipei City, Taiwan) and 5 µL of sterile distilled water in a G-STORM GS1 thermal cycler (Gene Technologies Ltd., Somerset, UK).

PCR was performed by using the conditions described below. The initial denaturation was performed at 94℃ for 2 min. The cycle parameters were as follows: 10 cycles of 10 sec at 94℃ and 60 sec at 69℃, then 20 cycles of 30 sec at 94℃, 60 sec at 62℃, and 30 sec at 72℃. The last step was a final extension for 5 min at 72℃. PCR products were electrophoresed at 100 volts with a 1.5% agarose gel using 1× Tris borate ethylenediaminetetraacetate (TBE) buffer. Products were visualized under a blue-light transilluminator. The PCR product sizes of the *FY^\*^A^ES^*, *FY^\*^B^ES^*, *FY^\*^A*, and *FY^\*^B* alleles were each 711 bp, whereas that of the internal control (i.e., the *HGH* gene) was 434 bp.

Known DNA samples for the Fy(a+b-), Fy(a-b+), Fy(a+b+), and Fy(a-b-) phenotypes were used as controls. In total, 500 DNA samples obtained from Thai blood donors and four DNA samples from the Guinea family were tested.

5. DNA sequencing
-----------------

To validate our in-house PCR-SSP technique for FY blood group genotyping, genomic DNA samples of eight genotyped blood donors (three, *FY^\*^A/FY^\*^A*; three, *FY^\*^A/FY^\*^B*; and two *FY^\*^B/FY^\*^B*) were sequenced. Additionally, four DNA samples obtained from the Guinea family were sequenced to confirm the FY phenotype results. A fragment of 931 bp containing both polymorphisms (c.125G\>A and c.-33T\>C) was obtained by PCR amplification of genomic DNA using the forward primer 5\'-GTGTAGTCCCAACCAGCCAA-3\' and reverse primer 5\'-AGGATACCCAGGACACTGGT-3\'. The PCR program consisted of one cycle of 95℃ for 5 min, followed by 30 cycles at 95℃ for 30 sec, 65℃ for 40 sec, and 72℃ for 30 sec, with a final extension at 72℃ for 5 min.

6. Statistical analysis
-----------------------

Gene frequencies were calculated by the gene-counting method. The chi-square (χ^2^) test was used to evaluate whether the observed genotype frequencies were in agreement with the expected frequencies under Hardy-Weinberg equilibrium. The χ^2^ test of homogeneity was used to determine the difference between Thai and other Asian populations. A *P* value of equal to or less than 0.05 was considered statistically significant. In addition, the probability of successfully obtaining antigen-negative RBCs for alloimmunized patients was calculated by dividing the number of antigen-negative units desired by the incidence of antigen-negative individuals in the donor population \[[@B20]\].

RESULTS
=======

The distribution of Duffy blood group phenotypes among 200 Thai blood donors was examined. Fy(a+b-) was the most common phenotype (177/200, 88.5%), followed by Fy(a+b+) (22/200, 11.0%), and Fy(a-b+) (1/200, 0.5%); and Fy(a-b-) was not found. Five hundred DNA samples included 200 samples with known phenotypes and an additional 300 samples that were genotyped for *FY* alleles by in-house PCR-SSP. The DNA controls were tested with four sets of primer combinations and the results were in agreement. According to the PCR-SSP results, *FY^\*^A/FY^\*^A* and *FY^\*^B/FY^\*^B* samples were positive with only the set of FY-AB-F and FY-A-R primers and the set of FY-AB-F and FY-B-R primers, respectively. In addition, *FY^\*^A/FY^\*^B* samples were positive with both sets of primers.

The FY genotyping results for the 200 samples with known phenotypes were in 100% concordance with the phenotyping results obtained using the gel technique. Moreover, PCR-SSP was used to determine the FY genotype of 300 DNA samples. *FY^\*^A/FY^\*^A* was the most common allele (464/500), followed by *FY^\*^A/FY^\*^B* (34/500) and *FY^\*^B/FY^\*^B* (2/500); the *FY^\*^A^ES^* and *FY^\*^B^ES^* alleles were not observed in this study. Additionally, the PCR-SSP technique was validated by using eight randomly chosen DNA samples by DNA sequencing and the results were in agreement ([Fig. 1](#F1){ref-type="fig"}).

The *FY* genotypes of the 500 Thai blood donors determined in this study were consistent with Hardy-Weinberg equilibrium (χ^2^=1.1133, *P*=0.736). The allele frequencies of *FY^\*^A* and *FY^\*^B* in the central Thailand population were 0.962 (962/1,000) and 0.038 (38/1,000), respectively. Duffy blood group allele frequencies in the Thai population and other Asian populations were compared. The observed allele frequencies were similar to those found in Chinese populations \[[@B17][@B21]\] and were significantly different from those of Japanese, Korean, and Malaysian populations ([Table 2](#T2){ref-type="table"}) \[[@B14][@B22][@B23]\].

Four blood samples from the Guinea family, with Fy(a-b-) phenotypes, were genotyped by using PCR-SSP and confirmed by DNA sequencing. Using PCR-SSP, positive results were obtained for all four samples using only the set of GATA-AB-F and FY-B-R primers, similar to the DNA control samples with Fy(a-b-) phenotypes of *FY^\*^B^ES^/FY^\*^B^ES^* (c.-33C). In addition, DNA sequencing results for the Guinea family also confirmed a point mutation in the GATA promoter region of *FY^\*^B^ES^*.

Using PCR-SSP for FY genotyping of 500 samples, the predicted phenotypes for each blood sample were summarized; *FY^\*^A/FY^\*^A* was Fy(a+b-) (92.8%), *FY^\*^A/FY^\*^B* was Fy(a+b+) (6.8%), and *FY^\*^B/FY^\*^B* was Fy(a-b+) (0.4%). Even though the *FY^\*^A^ES^* and *FY^\*^B^ES^* alleles were not detected in this study, the presence of *FY^\*^A^ES^/FY^\*^A^ES^*, *FY^\*^B^ES^/FY^\*^B^ES^*, and *FY^\*^A^ES^/FY^\*^B^ES^* can be predicted to be associated with the Fy(a-b-) phenotype.

In this study, only two Fy(a-b+) samples were found among 500 Thai blood donors. For a patient with the Fy(a-b+) phenotype who has anti-Fy^a^ and requires a blood transfusion, the probability of successfully providing antigen-negative RBCs from individuals with the Fy(a-b+) phenotype among Thai blood donors for crossmatching was calculated. In this case, when two units are required, testing at least 500 random units should yield two Fy(a-b+) units \[2/0.004\]. If this patient has multiple antibodies, such as anti-Fy^a^ and anti-E, 755 random units \[2/0.004×0.662\] would need to be tested to find two compatible units \[[@B5][@B20]\].

DISCUSSION
==========

In this study, the Duffy blood group phenotypes and the predicted phenotypes in 200 and 300 Thai blood donors confirmed that the Fy(a+b-) phenotype was the most common, followed by Fy(a+b+) and Fy(a-b+), similar to other studies in Thai populations \[[@B5][@B19][@B24]\]. Fy(a-b-), a rare phenotype, was not observed. Routinely, FY blood group phenotyping requires an indirect antiglobulin phase; hence, it is difficult to type RBCs of multitransfused patients on the basis of a positive direct antiglobulin test.

After FY blood group genotyping using in-house PCR-SSP, the genotyping results, including *FY^\*^A*, *FY^\*^B*, *FY^\*^A^ES^*, and *FY^\*^B^ES^* allele detection, were computed for all four predicted phenotypes. The validated in-house PCR-SSP genotyping results were confirmed by DNA sequencing. Moreover, the fidelity of the genotyping technique was high based on the 100% concordance between the genotyping and phenotyping results.

As previously reported in multitransfused Thai patients, anti-Fy^b^ was frequently found together with other blood group antibodies \[[@B8]\]; as a consequence, the difficulty in finding compatible RBCs depends on the prevalence of antibody combinations. Although anti-Fy3 has not been reported in Thai patients, we included *FY^\*^A^ES^* and *FY^\*^B^ES^* allele detection in our PCR-SSP analysis. Owing to the large population of multi-ethnic residents in Bangkok, a higher number of individuals with rare blood phenotypes in donors and patients could be found.

In a previous study, not only limited phenotype matching (D, C, c, E, e, and K), but also extended phenotype matching of S, Fy^a^, and Jk^b^ was suggested for transfusion in patients with sickle cell disease \[[@B25]\]. In Thailand, the prevalence of thalassemia patients requiring repeated blood transfusions is high; therefore, the implementation of extended FY genotyping for both *FY^\*^A* and *FY^\*^B* in donors and patients would be beneficial for the prevention of alloimmunization. In our examination of the Guinea family, we also confirmed that the Fy(a-b-) phenotype was associated with homozygous *FY^\*^B^ES^* alleles by PCR-SSP and DNA sequencing in all samples. Hence, the probability of finding extended-matched donors in Thai populations is unlikely for Fy(a-b-) patients. In this case, autologous or family-related donations are recommended. In addition, the in-house PCR-SSP technique is simple, convenient, and reproducible. Interestingly, it could reduce the mutagenic and toxic effects of ethidium bromide to visualize fragments. Owing to the remarkably rare observation of the *FY^\*^X* allele in Asian populations \[[@B10][@B12]\], the in-house PCR-SSP does not include the detection of this allele.

This is the first report of *FY* blood group allele frequencies in the Thai population. The *FY^\*^A* allele was the most common and its frequency was similar to that observed in Chinese populations \[[@B17][@B21]\]; but it was statistically significantly different (*P*\<0.05) from that in Korean, Japanese, and Malaysian populations \[[@B14][@B22][@B23]\]. A recent study compared the Kidd blood group allele frequencies in two Thai blood donors \[[@B26]\], and found that Kidd blood group allele frequencies in Thai individuals were statistically different from those of Japanese individuals, but similar to those of Chinese individuals \[[@B21]\]. Therefore, the analysis of various RBC gene divergences among populations could provide insight into national history, human origins, and migration patterns.

In conclusion, our study confirms a high frequency of the *FY^\*^A* allele in the Thai population. At least 500 Thai blood donors are needed to obtain two units of antigen RBCs for the Fy(a-b+) phenotype.

This work was supported by grants from the Thammasat University Fund and the Higher Education Research Promotion and National Research University Project of Thailand, Office of the Higher Education Commission.

**Authors\' Disclosures of Potential Conflicts of Interest:** No potential conflicts of interest relevant to this article were reported.

![Electropherograms of the *FY* gene at the GATA box motif of the promoter region, single nucleotide polymorphism (SNP) c.-33T\>C (column A) and the *FY^\*^A* and *FY^\*^B* polymorphism region, SNP c.125G\>A (column B). DNA sequences of the *FY^\*^A* homozygote (1), the *FY^\*^B* homozygote (2), the *FY^\*^A/FY^\*^B* heterozygote (3), and the *FY^\*^B^ES^* homozygote (4) are amplified in both regions.](alm-35-618-g001){#F1}

###### Primer sequences for FY blood group genotyping

![](alm-35-618-i001)

  Allele          Primer                       Primer sequence (5\'→3\')   Product size (bp)   Final concentration (µM)
  --------------- ---------------------------- --------------------------- ------------------- --------------------------
  *FY^\*^A^ES^*   GATA-AB-F                    CTCATTAGTCCTTGGCTCTTAC      711                 0.5
  FY-A-R          AGCTGCTTCCAGGTTGGCAC                                                         
  *FY^\*^B^ES^*   GATA-AB-F                    CTCATTAGTCCTTGGCTCTTAC      711                 0.5
  FY-B-R          AGCTGCTTCCAGGTTGGCAT                                                         
  *FY^\*^A*       FY-AB-F                      CTCATTAGTCCTTGGCTCTTAT      711                 0.5
  FY-A-R          AGCTGCTTCCAGGTTGGCAC                                                         
  *FY^\*^B*       FY-AB-F                      CTCATTAGTCCTTGGCTCTTAT      711                 0.5
  FY-B-R          AGCTGCTTCCAGGTTGGCAT                                                         
  *HGH*           HGH-F                        TGCCTTCCCAACCATTCCCTTA      434                 0.5
  HGH-R           CCACTCACGGATTTCTGTTGTGTTTC                                                   

Abbreviations: HGH, human growth hormone; ES, erythrocyte silent.

###### *FY^\*^A* and *FY^\*^B* allele frequencies in Asian populations

![](alm-35-618-i002)

  Population                                  Number   *FY^\*^A*   *FY^\*^B*   Method     *P* value
  ------------------------------------------- -------- ----------- ----------- ---------- -----------
  Thais (present study)                       500      0.962       0.038       PCR-SSP    \-
  Brazilian Japanese descendants \[[@B14]\]   209      0.785       0.215       PCR-RFLP   \< 0.001
  Jiangsu Chinese \[[@B21]\]                  146      0.938       0.062       PCR-SSP    0.114
  Dalian Chinese \[[@B17]\]                   120      0.933       0.067       PCR-ASP    0.075
  Korean \[[@B22]\]                           107      0.921       0.079       PCR-RFLP   0.014
  Malaysian \[[@B23]\]                        60       0.908       0.092       PCR-ASP    0.013

Abbreviations: SSP, sequence-specific primers; RFLP, restriction fragment length polymorphism; ASP, allele-specific primer.
